

Active substances set

Search phrase: everolimus

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant breast cancer

Everolimus

Everolimus is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO

Kidney cancer

Everolimus

Everolimus is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO